AndreaBozzo/ceres-open-data-index huggingface dataset:
Weekly Cumulative Doses (in Millions) of Influenza Vaccines Distributed by Season, United States

• Weekly Cumulative Doses (in Millions) of Influenza Vaccines Distributed by Season in the United States. • Influenza vaccine is produced by private manufacturers. These data are submitted to CDC by current U.S.─ licensed manufacturers of influenza vaccine and a subset of influenza vaccine wholesalers and distributors that receive vaccine directly from these manufacturers. These data are not projected but approximate all influenza vaccines distributed in the United States.
Weekly Cumulative Doses (in Millions) of Influenza Vaccine Distributed by Flu Season in the United States

Weekly Cumulative Doses (in Millions) of Influenza Vaccine Distributed by Flu Season in the United States • Archived data are available here: https://data.cdc.gov/resource/e5zk-7tx5 • Flu vaccine is produced by private manufacturers, so supply depends on manufacturers. Vaccine manufacturers have projected that they will supply the United States with as many as 173.5 million to 183.5 million doses of influenza vaccines for the 2022-2023 season. • Additional information is available: https://www.cdc.gov/flu/prevent/vaccine-supply-distribution.htm.
Weekly Cumulative COVID-19 Vaccination Coverage Map and Comparison Between 2025–26 and Previous Seasons, Overall, by Jurisdiction Among Adults 18 Years

• Weekly COVID-19 Vaccination Coverage of Adults 18 Years and Older by Jurisdiction • Weekly estimates of COVID-19 vaccination coverage and intent for vaccination among adults are calculated using data from the National Immunization Surveys (NIS)-Fall Respiratory Virus Module (NIS-FRVM) (https://www.cdc.gov/nis/about/index.html). • The NIS–FRVM is an ongoing random-digit-dial cellular telephone survey of households with adults 18 years and older. All estimates are based upon self-reported receipt of vaccination and month of that vaccination. • Weekly comparisons to previous season should take into account differences between seasons in vaccine availability dates. 2023–24 COVID-19 vaccines were first available mid-September 2023, and 2024–25 and 2025–26 COVID-19 vaccines were first available at the end of August 2024 and 2025, respectively.
Weekly Cumulative COVID-19 Vaccination Coverage, by Season and Race and Ethnicity, Medicare Fee-For-Service Beneficiaries aged ≥65 years

• COVID-19 vaccination coverage among Medicare fee-for-service beneficiaries aged 65 years and older is assessed using data files from the Medicare Fee-For-Service (FFS) administrative claims data managed by the Centers for Medicare & Medicaid Services (CMS). • Weekly COVID-19 vaccination coverage estimates were calculated using Kaplan-Meier survival analysis, based on beneficiaries enrolled as of August 1 of each year. For the 2025 ̶26 season, COVID-19 vaccines received since August 27, 2025, were included.*
Weekly COVID-19 Vaccination Coverage among Pregnant Women by Race and Ethnicity

Weekly COVID-19 Vaccination Coverage, Pregnant Women 18-49 Years Old • COVID-19 vaccination coverage among pregnant women is assessed through the Vaccine Safety Datalink* • Data on updated 2023-24 COVID-19 vaccinations among pregnant women was available starting September 23, 2023, and includes doses received starting September 14, 2023.
Weekly COVID-19 cases among persons ≥5 years old among unvaccinated and vaccinated with a BNT162b2 (Pfizer-BioNTech) primary series by age group — 22 U.S. jurisdictions, January 16 to May 28, 2022

Reported numbers of SARS-CoV-2 infections by age group (5–11, 12–17, 18–49, 50–64, ≥65 years of age) from 22 U.S. jurisdictions (AR, AZ, CA, CO, CT, DC, FL, GA, IN, KS, MI, MA, MN, NC, NE, NJ, NM, NYC, PHL, TN, UT, WI ); ~53% of the U.S. population) with routine linkages between COVID-19 case surveillance and immunization information system (IIS) data reported to CDC during January 16, 2022 – May 28, 2022. Vaccine administration (coverage) data reported to CDC were aggregated by U.S. reporting jurisdiction, MMWR week of vaccination (≥14 days after completing the primary vaccine series), FDA-approved vaccine products, and age group (5–11, 12–17, 18–49, 50–64, ≥65 years). Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing BNT162b2 (Pfizer-BioNTech) primary series. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. To estimate the number of unvaccinated persons in each MMWR week, the 2019 U.S. Census population estimates by jurisdiction and age group were used (except for California, where State Department of Finance 2021 population projections were determined to be more accurate). The number of unvaccinated persons each MMWR week was estimated by subtracting the cumulative number of vaccinated (all products) and partially vaccinated persons (all products) from the respective population totals for each jurisdiction and age group. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent rates from growing unrealistically large due to potential overestimates of vaccination coverage.
Weekly Counts of Deaths by Jurisdiction, and Race and Hispanic Origin

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. This visualization provides weekly data on the number of deaths from all causes by jurisdiction of occurrence and race and Hispanic origin. Numbers of deaths are also shown for all causes excluding COVID-19, and for COVID-19. Counts of deaths in more recent weeks can be compared with counts from earlier years to determine if the number is higher than expected.
Weekly Counts of Death by Jurisdiction and Select Causes of Death

Effective September 27, 2023, this dataset will no longer be updated. Similar data are accessible from wonder.cdc.gov. This visualization provides weekly data on the number of deaths by jurisdiction of occurrence and cause of death. Counts of deaths in more recent weeks can be compared with counts from earlier years to determine if the number is higher than expected. Selected causes of death are shown, based on analyses of the most prevalent comorbid conditions reported on death certificates where COVID-19 was listed as a cause of death (see https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm#Comorbidities). Cause of death counts are based on the underlying cause of death, and presented for Respiratory diseases, Circulatory diseases, Malignant neoplasms, and Alzheimer disease and dementia. Estimated numbers of deaths due to these other causes of death could represent misclassified COVID-19 deaths, or potentially could be indirectly related to COVID-19 (e.g., deaths from other causes occurring in the context of health care shortages or overburdened health care systems). Deaths with an underlying cause of death of COVID-19 are not included in these estimates of deaths due to other causes. Deaths due to external causes (i.e. injuries) or unknown causes are excluded. For more detail, see the Technical Notes.
Water Fluoridation Statistics - Percent of PWS population receiving fluoridated water

2000-2018. Water Fluoridation Statistics is a biennial report of the percentage and number of people receiving fluoridated water from 2000 through 2018, originally published at http://www.cdc.gov/fluoridation/statistics/index.htm. For more information, see: http://www.cdc.gov/oralhealthdata/overview/fluoridation_indicators.html
VSRR - State and National Provisional Counts for Live Births, Deaths, and Infant Deaths

NOTES: Figures include all revisions received from the states and, therefore, may differ from those previously published. Data are provisional and are subject to monthly reporting variation. National data are calculated by summing the number of events reported by state of residence; counts are rounded to the nearest thousand (births and deaths) or hundred (infant deaths). Provisional counts may differ by approximately 2% from final counts, due to rounding and reporting variation. Additionally, the accuracy of the provisional counts may change over time. Data are estimates by state of residence. For discussion of the nature, source, and limitations of the data, see "Technical Notes" of the report, Births, Marriages, Divorces, and Deaths: Provisional Data for 2009. Available from URL: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_25.htm. Final counts of births, deaths, and infant deaths for previous years can be obtained from http://wonder.cdc.gov. SOURCE: Provisional data from the National Vital Statistics System, National Center for Health Statistics, CDC.
VSRR Provisional Maternal Death Counts and Rates

This data presents national-level provisional maternal mortality rates based on a current flow of mortality and natality data in the National Vital Statistics System. Provisional rates which are an early estimate of the number of maternal deaths per 100,000 live births, are shown as of the date specified and may not include all deaths and births that occurred during a given time period (see Technical Notes). A maternal death is the death of a woman while pregnant or within 42 days of termination of pregnancy irrespective of the duration and the site of the pregnancy, from any cause related to or aggravated by the pregnancy or its management, but not from accidental or incidental causes. In this data visualization, maternal deaths are those deaths with an underlying cause of death assigned to International Statistical Classification of Diseases, 10th Revision (ICD-10) code numbers A34, O00–O95, and O98–O99. The provisional data include reported 12 month-ending provisional maternal mortality rates overall, by age, and by race and Hispanic origin. Provisional maternal mortality rates presented in this data visualization are for “12-month ending periods,” defined as the number of maternal deaths per 100,000 live births occurring in the 12-month period ending in the month indicated. For example, the 12-month ending period in June 2020 would include deaths and births occurring from July 1, 2019, through June 30, 2020. Evaluation of trends over time should compare estimates from year to year (June 2020 and June 2021), rather than month to month, to avoid overlapping time periods. In the visualization and in the accompanying data file, rates based on death counts less than 20 are suppressed in accordance with current NCHS standards of reliability for rates. Death counts between 1-9 in the data file are suppressed in accordance with National Center for Health Statistics (NCHS) confidentiality standards. Provisional data presented on this page will be updated on a quarterly basis as additional records are received. Previously released estimates are revised to include data and record updates received since the previous release. As a result, the reliability of estimates for a 12-month period ending with a specific month will improve with each quarterly release and estimates for previous time periods may change as new data and updates are received.
VSRR Provisional Drug Overdose Death Counts

This data presents provisional counts for drug overdose deaths based on a current flow of mortality data in the National Vital Statistics System. Counts for the most recent final annual data are provided for comparison. National provisional counts include deaths occurring within the 50 states and the District of Columbia as of the date specified and may not include all deaths that occurred during a given time period. Provisional counts are often incomplete and causes of death may be pending investigation resulting in an underestimate relative to final counts. To address this, methods were developed to adjust provisional counts for reporting delays by generating a set of predicted provisional counts. Several data quality metrics, including the percent completeness in overall death reporting, percentage of deaths with cause of death pending further investigation, and the percentage of drug overdose deaths with specific drugs or drug classes reported are included to aid in interpretation of provisional data as these measures are related to the accuracy of provisional counts. Reporting of the specific drugs and drug classes involved in drug overdose deaths varies by jurisdiction, and comparisons of death rates involving specific drugs across selected jurisdictions should not be made. Provisional data presented will be updated on a monthly basis as additional records are received. For more information please visit: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm
Visits to physician offices, hospital outpatient departments, and hospital emergency departments, by age, sex, and race: United States

Data on visits to physician offices, hospital outpatient departments and hospital emergency departments by selected population characteristics. Please refer to the PDF or Excel version of this table in the HUS 2019 Data Finder (https://www.cdc.gov/nchs/hus/contents2019.htm) for critical information about measures, definitions, and changes over time. Note that the data file available here has more recent years of data than what is shown in the PDF or Excel version. Data for 2017 physician office visits are not available. SOURCE: NCHS, National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey. For more information on the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey, see the corresponding Appendix entries at https://www.cdc.gov/nchs/data/hus/hus17_appendix.pdf.
Vision Service Plan (VSP) – Vision and Eye Health Surveillance

2016. This dataset is a de-identified summary table of vision and eye health data indicators from VSP, stratified by all available combinations of age group, race/ethnicity, sex, and state. VSP claims for VEHSS provides a convenience sample of vision insurance members representing approximately more than 1 in 4 of the U.S. population. VSP uses a web-based claims submissions system to collect and process claims. The denominator of the rates represents persons with VSP benefits as reported by employers, and is subject to some uncertainty. VSP data for VEHSS include Service Utilization and Eye Health Condition indicators. Certain ophthalmic conditions and procedures are covered by health insurance and are not covered by managed vision insurance, claims based eye disease prevalence may therefore be expected to undercount true prevalence. Person level claims and person counts are not publically available. Reported rates were suppressed for de-identification to ensure protection of patient privacy. Detailed information on VEHSS VSP analyses can be found on the VEHSS VSP webpage (link). Information on VSP data can be found on the VSP website (www.vsp.com). The VEHSS VSP dataset was last updated in June 2018.
VEHSS Medicare Fee for Service + Advantage (100%)

2021, 2022. This dataset is a de-identified summary table of vision and eye health data indicators from Medicare claims and encounters, stratified by all available combinations of age group, race/ethnicity, gender, and state. Medicare FFS + Advantage data for VEHSS includes beneficiaries who were fully enrolled in Medicare Part B (Fee-for-Service (FFS)) or Medicare Part C (Medicare Advantage) for the duration of the year. Medicare claims provide a convenience sample that is approximately representative of the US population aged 65 and older, and contains data for certain individuals younger than age 65 who are eligible for Medicare for other reasons, including disability due to blindness. Medicare data for VEHSS include Service Utilization and Medical Diagnoses indicators. Data were suppressed for de-identification to ensure protection of patient privacy. Data will be updated as it becomes available. Historical data for Medicare FFS only is available on VEHSS from 2014. Detailed information on VEHSS Medicare analyses can be found on the VEHSS Medicare webpage (cdc.gov/visionhealth/vehss/data/claims/medicare.html). Information on available Medicare claims data can be found on the ResDac website (www.resdac.org). The VEHSS Medicare dataset was last updated August 2025.
Vaccine Hesitancy for COVID-19: Public Use Microdata Areas (PUMAs)

Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy. To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates(https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data. We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS)(https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates in more granular areas using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). Public Use Microdata Areas (PUMA) level – PUMAs are geographic areas within each state that contain no fewer than 100,000 people. PUMAs can consist of part of a single densely populated county or can combine parts or all of multiple counties that are less densely populated. The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31. County and State Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-County-and-local-es/q9mh-h2tw
Vaccine Hesitancy for COVID-19: County and local estimates

Due to the change in the survey instrument regarding intention to vaccinate, our estimates for “hesitant or unsure” or “hesitant” derived from April 14-26, 2021, are not directly comparable with prior Household Pulse Survey data and should not be used to examine trends in hesitancy. To support state and local communication and outreach efforts, ASPE developed state, county, and sub-state level predictions of hesitancy rates (https://aspe.hhs.gov/pdf-report/vaccine-hesitancy) using the most recently available federal survey data. We estimate hesitancy rates at the state level using the U.S. Census Bureau’s Household Pulse Survey (HPS) (https://www.census.gov/programs-surveys/household-pulse-survey.html) data and utilize the estimated values to predict hesitancy rates at the Public Use Microdata Areas (PUMA) level using the Census Bureau’s 2019 American Community Survey (ACS) 1-year Public Use Microdata Sample (PUMS)(https://www.census.gov/programs-surveys/acs/microdata.html). To create county-level estimates, we used a PUMA-to-county crosswalk from the Missouri Census Data Center(https://mcdc.missouri.edu/applications/geocorr2014.html). PUMAs spanning multiple counties had their estimates apportioned across those counties based on overall 2010 Census populations. The HPS is nationally representative and includes information on U.S. residents’ intentions to receive the COVID-19 vaccine when available, as well as other sociodemographic and geographic (state, region and metropolitan statistical areas) information. The ACS is a nationally representative survey, and it provides key sociodemographic and geographic (state, region, PUMAs, county) information. We utilized data for the survey collection period May 26, 2021 – June 7, 2021, which the HPS refers to as Week 31.. PUMA COVID-19 Hesitancy Data - https://data.cdc.gov/Vaccinations/Vaccine-Hesitancy-for-COVID-19-Public-Use-Microdat/djj9-kh3p
Vaccination Coverage among Pregnant Women

Vaccination Coverage among Pregnant Women • Data on influenza and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccination coverage at the state level from the Pregnancy Risk Assessment Monitoring System (PRAMS) for women who had a recent live birth by age and race/ethnicity. • Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/index.html and https://www.cdc.gov/flu/fluvaxview/index.htm
Vaccination Coverage among Nursing Home Residents

Vaccination Coverage among Nursing Home Residents • Data on influenza and pneumococcal vaccination coverage from the Long-Term Care Minimum Data Set (MDS) from the Centers for Medicare & Medicaid Services (CMS) at the national, regional, and state levels by sociodemographic characteristics. • Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/adultvaxview/index.html and https://www.cdc.gov/flu/fluvaxview/index.htm
Vaccination Coverage among Adolescents (13-17 Years)

Vaccination Coverage among Adolescents (13-17 Years) • Data on adolescent vaccination coverage and selected sociodemographic characteristics by State, HHS Region, and the United States from the National Immunization Survey-Teen (NIS-Teen). • Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/teenvaxview/index.html
US Census Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States

2010-2018; 2019. US Census Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States. The estimates for the 2010-2018 dataset are based on the 2010 Census and reflect changes to the April 1, 2010 population due to the Count Question Resolution program and geographic program revisions. Median age is calculated based on single year of age. The estimates for 2019 are based on a one-year dataset that was published on the US Census website in 2021. For population estimates methodology statements, see http://www.census.gov/popest/methodology/index.html.
University of Illinois at Chicago Health Policy Center - Funding

1991-2016. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Funding Data, Appropriations (1991-2016) and Expenditures (2008-2016). Appropriations data show public funds allocated to/by a particular state for tobacco prevention and control. They are not necessarily expended. Appropriations are from four major funding sources, Federal, state, Robert Wood Johnson Foundation (RWJF), and the American Legacy Foundation (Legacy). Expenditures are amounts spent by state tobacco control programs on tobacco prevention and control. Expenditure data are available by CDC Best Practices Program Components (State and Community Interventions, Health Communication Interventions, Cessation Interventions, Surveillance and Evaluation, and Administration and Management). Expenditures from 2008 to 2014 are compared against 2007 CDC Best Practices Recommendations; expenditures from 2015 and forward are compared against 2014 CDC Best Practices Recommendations.